Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial

医学 安慰剂 便秘 慢性便秘 内科学 临床试验 不利影响 随机对照试验 胃肠病学 病理 替代医学
作者
Atsushi Nakajima,Mitsunori Seki,Shinya Taniguchi,Akira Ohta,Per-Göran Gillberg,Jan P. Mattsson,Michael Camilleri
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:3 (8): 537-547 被引量:140
标识
DOI:10.1016/s2468-1253(18)30123-7
摘要

A subset of patients with constipation has reduced colonic bile acid concentrations, which are associated with slow colonic transit. In a previous study, elobixibat, a locally acting ileal bile acid transporter inhibitor, accelerated colonic transit in Japanese patients with functional constipation. In this study, we aimed to determine the efficacy of elobixibat for short-term treatment of chronic constipation, and safety, patient satisfaction, and quality of life with long-term treatment.We did two phase 3 studies of patients aged 20-80 years in Japan with at least 6 months of chronic constipation, who satisfied Rome III criteria for functional constipation, including fewer than three spontaneous bowel movements per week. The first trial, including patients enrolled at 16 clinics, was a 2-week, randomised, double-blind, placebo-controlled study in which (after a 2-week run-in period) patients were randomly assigned (1:1) to either elobixibat 10 mg/day for 2 weeks or placebo. Randomisation was done with permuted block method (block size six) without stratification. Masking to treatment allocation was achieved with identical appearances of elobixibat and placebo, which were supplied in sealed, opaque containers. Group assignment was concealed from patients, investigators, and analysts. The second trial, including patients enrolled at 34 clinics or hospitals, was an open-label, 1-year study in which all patients received elobixibat; participants could titrate the dose to 5 mg/day or 15 mg/day, or maintain the 10 mg/day dose. In both studies, participants took the study drug as an oral tablet once per day before breakfast. The primary outcome of the 2-week randomised trial was the change from baseline (ie, last week of the 2-week run-in) in the frequency of spontaneous bowel movements during week 1 of treatment. The primary outcome of the 52-week open-label trial was safety (type, severity, and incidence of adverse drug reactions) at all times from treatment initiation. All efficacy analyses were based on the modified intention-to-treat (ITT) population without imputation for any missing data. Safety analyses included all patients who received at least one dose of study drug. These trials are registered with the Japan Pharmaceutical Information Center (numbers JapicCTI-153061 and JapicCTI-153062) and have been completed.Between Nov 4, 2015, and June 11, 2016, we assigned 133 patients to treatment in the 2-week randomised trial: 70 to elobixibat (69 included in the modified ITT and safety populations) and 63 to placebo. The frequency of spontaneous bowel movements per week during week 1 of treatment was greater with elobixibat (least-squares mean 6·4, 95% CI 5·3-7·6) than with placebo (1·7, 1·2-2·2), p<0·0001). Between Oct 31, 2015, and March 15, 2017, we allocated 341 patients to 52 weeks of elobixibat (340 included in the modified ITT and safety populations). 163 (48%) patients in the 52-week trial had an adverse drug reaction, the most common of which were mild gastrointestinal disorders (in 135 [40%] patients). Inguinal hernia was reported in one patient with elobixibat in the 52-week study as a moderate adverse drug reaction. The most common adverse drug reactions in both trials were mild abdominal pain (13 [19%] patients with elobixibat and one [2%] with placebo in the 2-week randomised trial, and 82 [24%] patients in the 52-week trial) and diarrhoea (nine [13%] patients with elobixibat and none with placebo in the 2-week randomised trial and 50 [15%] in the 52-week trial).Elobixibat resolved constipation in the short-term, and was well tolerated with both short-term and long-term treatment. The evidence supports the use of this novel approach to increase intracolonic concentrations of endogenous bile acid for the treatment of chronic constipation.EA Pharma and Mochida Pharmaceutical.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
aa完成签到,获得积分10
1秒前
快乐仙知发布了新的文献求助10
2秒前
CipherSage应助CornellRong采纳,获得200
2秒前
11完成签到,获得积分10
4秒前
风铃鸟完成签到,获得积分10
7秒前
fd163c完成签到,获得积分10
8秒前
8秒前
hsx发布了新的文献求助30
9秒前
哈牛完成签到 ,获得积分10
9秒前
Lucas应助温婉的翎采纳,获得10
10秒前
风铃鸟发布了新的文献求助10
10秒前
521完成签到,获得积分20
10秒前
future完成签到 ,获得积分10
15秒前
脾气暴躁的小兔完成签到,获得积分10
16秒前
慕青应助噜噜采纳,获得10
16秒前
乐观期待完成签到,获得积分10
19秒前
19秒前
21秒前
噜噜完成签到,获得积分10
22秒前
JJ发布了新的文献求助10
23秒前
SciGPT应助Charlie采纳,获得10
24秒前
所所应助jenny_shjn采纳,获得10
25秒前
噜噜发布了新的文献求助10
27秒前
28秒前
fyjlfy完成签到 ,获得积分10
29秒前
勿明应助刀锋采纳,获得50
34秒前
35秒前
大气金毛完成签到 ,获得积分10
36秒前
huahua发布了新的文献求助10
41秒前
Limerencia完成签到,获得积分10
41秒前
考拉发布了新的文献求助10
42秒前
Linden_bd完成签到 ,获得积分10
42秒前
唐新惠完成签到 ,获得积分10
42秒前
充电宝应助你想读博吗采纳,获得10
43秒前
lightgo应助科研通管家采纳,获得10
45秒前
华仔应助科研通管家采纳,获得10
46秒前
思源应助科研通管家采纳,获得10
46秒前
充电宝应助科研通管家采纳,获得10
46秒前
lightgo应助科研通管家采纳,获得10
46秒前
46秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
T/CIET 1202-2025 可吸收再生氧化纤维素止血材料 500
Interpretation of Mass Spectra, Fourth Edition 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3950988
求助须知:如何正确求助?哪些是违规求助? 3496397
关于积分的说明 11081817
捐赠科研通 3226886
什么是DOI,文献DOI怎么找? 1784005
邀请新用户注册赠送积分活动 868114
科研通“疑难数据库(出版商)”最低求助积分说明 800997